Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372502 · ClinicalTrials.gov registry record · NA
Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation
A NA study of Septic Shock and Severe Sepsis, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT00372502: Completed NA study of Septic Shock and Severe Sepsis, sponsored by National Institute of General Medical Sciences (NIGMS).
NCT00372502 is a NA study of Septic Shock and Severe Sepsis that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 300 participants, below the 5,047-participant average among 24 other Septic Shock trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00372502, a NA study of Septic Shock and Severe Sepsis, has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if there is equivalence between two different methods of treating patients with severe bloodstream infection called sepsis. We will randomly assign patients to one of two treatment methods. One of the treatment methods is the current standard of care and uses an infrared sensor on the end of a catheter to determine the adequacy of treatment. The second treatment method is identical to the first but instead of the infrared sensor a blood test that is performed as a part of standard care (with blood drawn from the catheter) will be used to determine the adequacy of treatment. This study will attempt to determine an easier method of guiding treatment.
Conditions Studied
Interventions
- PROCEDURE Modified EGDT
- PROCEDURE Standard EGDT
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
New Jersey
- Cooper Hospital - Camden
North Carolina
- Carolinas Medical Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-12 |
| Phase | NA |
What the finished NCT00372502 record still lists
NCT00372502 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 5,047-participant average among 24 other Septic Shock trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Septic Shock appearing as the primary indexed condition, and to 2 interventions - of which Modified EGDT is the first listed.
NCT00372502 reports a single indexed study location in Massachusetts, New Jersey, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00372502 about?
NCT00372502 is a clinical study titled "Clinical Trial of the Optimal Endpoint of Early Sepsis Resuscitation". The purpose of this study is to determine if there is equivalence between two different methods of treating patients with severe bloodstream infection called sepsis. We will randomly assign patients to one of two treatment methods. One of the treatment methods is the current standard of care and use...
What is the current status of trial NCT00372502?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2007-01. Estimated completion is 2008-12.
What conditions does trial NCT00372502 study?
This clinical trial studies the following conditions: Septic Shock, Severe Sepsis.
What interventions are being tested in trial NCT00372502?
The interventions under investigation include: Modified EGDT (PROCEDURE), Standard EGDT (PROCEDURE).
Who is sponsoring clinical trial NCT00372502?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00372502 being conducted?
This trial has 3 study locations across Massachusetts, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Septic Shock
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00372502's enrollment target sits among peer trials
300 11th of 24 higher than 13 of 24 other Septic Shock trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Septic Shock trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
-
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
RECRUITING · NA
-
Assessment for Implementation Methods in Sepsis
RECRUITING · NA
-
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
RECRUITING · NA
-
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
ACTIVE NOT RECRUITING · NA
-
Blood Purification for the Treatment of Pathogen Associated Shock
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia